The next 6 to 8 months are going to be very interesting for Cogstate. If the FDA approves Abucanumab, overnight healthcare systems around the world are going to need a triage tool to quickly, easily and consistently measure cognition. There are only 3 or 4 choices that are approved, tested and ready to go and Cogstate will be the first cab of the rank. You could easily be looking at hundreds of thousands of administered Cognigrams next year, with that number building in the many millions per year in subsequent years. Pick your pricing point per test US$ 5, US$ 10, US$ 15 ? Gross margins will be sky high. Add this to a business that will already profitable and you have a pretty attractive business. I don't think we will see many of the larger holders thinking about selling ahead of this decision.
CGS Price at posting:
67.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)